RESUMO
The main reason for the ineffectiveness of antiviral therapy in patients with chronic hepatitis C that impedes full and adequate treatment of IFN-α and ribavirin is the development of neutropenia and thrombocytopenia. The present study included 63 patients (59% men and 41% women) with chronic hepatitis C that did not previously receive antiviral therapy. All patients had HCV genotype-1 (15 patients with genotype 1a; 42 people, with genotype 1b; 6 patients, with genotypes (1a + 1b)). The patients' age was 33.8 ± 0.7 years, with term of infection 6,1 ± 0,8 years. It was shown that in the case of treatment with Peg-IFN-alpha in combination with ribavirin, a significant decrease in the number of white blood cells, neutrophils and platelets prevailed in patients with HCV-monoinfected genotype 1b in the F0-F2 stages (2,8-8,6 kPa) at METAVIR. With the development of moderate "early" (less than 12 weeks of antiviral therapy) and for the prevention of "late" (more than 12 weeks of treatment) neutropenia, appointment of immune medicine likopid (glucosaminylmuramyldipeptide) at a dosage of 1 mg, 2 times a day for 20 days, in patients with chronic hepatitis C (genotype 1b ) with Assuntos
Antivirais/uso terapêutico
, Genótipo
, Hepatite C Crônica/complicações
, Neutropenia/virologia
, Trombocitopenia/virologia
, Quimioterapia Combinada
, Feminino
, Hepacivirus
, Hepatite C Crônica/tratamento farmacológico
, Hepatite C Crônica/genética
, Humanos
, Interferon-alfa
, Masculino
, Pessoa de Meia-Idade
, Polietilenoglicóis
, Proteínas Recombinantes
, Ribavirina
, Resultado do Tratamento
RESUMO
OBJECTIVE: to evaluate the incidence of bacterial aggravations and antibiotics administration with analysis of effectiveness of antiviral therapy in ambulatory patients with acute viral respiratory infection (ARVI) and influenza. MATERIAL AND METHODS: International cohort open non-interventional .study <Assuntos
Antivirais
, Infecções Bacterianas
, Gossipol/análogos & derivados
, Influenza Humana
, Infecções Respiratórias
, Doença Aguda
, Adolescente
, Adulto
, Idoso
, Idoso de 80 Anos ou mais
, Antivirais/administração & dosagem
, Antivirais/efeitos adversos
, Infecções Bacterianas/induzido quimicamente
, Infecções Bacterianas/epidemiologia
, Estudos de Coortes
, Feminino
, Gossipol/administração & dosagem
, Gossipol/efeitos adversos
, Humanos
, Incidência
, Influenza Humana/tratamento farmacológico
, Influenza Humana/epidemiologia
, Masculino
, Pessoa de Meia-Idade
, Infecções Respiratórias/tratamento farmacológico
, Infecções Respiratórias/epidemiologia
, Infecções Respiratórias/virologia
RESUMO
The identification of the single nucleotide polymorphisms (SNP) at rs8099917 and rs12979860 loci of IL-28B gene is presently necessary for patients with the genotype HCV-1 to predict sustained viral response (SVR) in case of combined antiviral therapy with interferon and ribavirin. In addition to the implementation of the antiviral activity of IFN-α, interleukin-1ß (IL-1ß) and interferon-gamma (IFN-γ) are involved. The goal of this work was to evaluate the efficacy of the HCV therapy with cytokines in patients unresponsive to previous therapy with unfavorable genotypes of IL-28B gene. SVR was achieved in 44.4% of patients with an unfavorable IL-28B genetic background with biochemical response without serious adverse effects or unexpected adverse effects, thereby corroborating the inclusion of proven safety Betaleukin® and Ingaron in the schemes of the antiviral therapy in combination with standard interferon-α and ribavirin in patients with recurrent HCV-infection.